secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theriva Biologics, Inc. (TOVX)
CIK:        0000894158
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001104659-24-088680
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theriva Biologics Q2 2024 cash $16.6M, VIRAGE trial to complete enrollment in Q3
--------------------------------------------------------------------------------

- Cash $16.6M as of June 30, 2024 vs $23.2M at Dec 31, 2023; runway into Q2 2025.
- VIRAGE Phase 2b trial for VCN-01 in metastatic PDAC expected to complete enrollment in Q3 2024.
- FDA granted Fast Track Designation for VCN-01 in metastatic pancreatic adenocarcinoma.
- Goodwill impairment of $4.0M recorded due to stock price decline and increased discount rate.
- R&D expenses $3.0M, G&A $1.5M for Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/894158/000110465924088680/0001104659-24-088680-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/894158/000110465924088680/tm2421314d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-088680

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer